Alnylam (ALNY) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions...

The CAPItello─290 phase III trial for Truqap (capivasertib) in combination with paclitaxel in patients with locally advanced (inoperable) or...

JAZZ shares are down 5% as it fails to achieve statistical significance on the primary and key secondary endpoint in a mid-stage tremor study on...

Novo Nordisk (NVO) declines as a late-stage study of its uncontrolled hypertension and advanced chronic kidney disease candidate, ocedurenone, fails...

High blood pressure, also known as hypertension, is a common condition where the force of the blood against your artery walls is high enough that it...

Results of a phase 3 PURPOSE 1 HIV prevention study done among adolescent girls and young women in South Africa and Uganda show that there were no...

PharmAust raises $10m to finalise preparations for its pivotal adaptive Phase 2/3 STRIKE study. ...

OSAKA, Japan and CAMBRIDGE, Massachusetts, June 22, 2024 – Takeda (TSE:4502/NYSE:TAK) today presented positive results from its Phase 2b,...

Breast cancer is a complex disease with varying degrees of severity and treatment approaches. Central to understanding and managing breast cancer is...

Clinical stage biotechnology company PharmAust has received commitments to raise $10 million via an institutional placement with directors and...